Alexander Theodore "Sasha" Shulgin (June 17, 1925 – June 2, 2014) was an American biochemist, broad researcher of synthetic psychoactive compounds, and author of works regarding these, who independently explored the organic chemistry and pharmacology of such agents—in his mid-life and later, many through preparation in his home laboratory, and testing on himself. He is acknowledged to have introduced to broader use, in the late 1970s, the prior synthesized compound MDMA ("ecstasy"), in research psychopharmacology and in combination with conventional therapy, the latter through presentations and academic publications, including to psychologists; and for the rediscovery, occasional discovery, and regular synthesis and personal use and distribution, of possibly hundreds of psychoactive compounds (for their psychedelic and MDMA-like empathogenic bioactivities). As such, Shulgin is seen both as a pioneering and a controversial participant in the emergence of the broad use of psychedelics. In 1991 and 1997, he and his wife Ann Shulgin compiled the books PiHKAL and TiHKAL (Phenethylamines I Have Known And Loved, likewise for Tryptamines), from notebooks that extensively described their work and personal experiences with these two classes of psychoactive drugs. Shulgin documented the chemical synthesis of many of these compounds. Some of the syntheses catalogued by Shulgin in his books include chemicals in the 2C family (such as 2C-B), compounds of the DOx family (such as DOM), and tryptamines (such as 4-HO-MET and 4-HO-MiPT). In describing Shulgin's work in psychedelic research and his preparation and experimentation with psychedelic drugs, he has been dubbed the "godfather of ecstasy" (and to a much more limited extent, the "godfather of psychedelics"). Writing in 2005—in the decade before Shulgin's death—a retrospective by Drake Bennett of The New York Times Magazine noted that as a consequence of Shulgin's testing his various synthetic compounds "for activity by taking the chemicals himself ... most of the scientific community consider[ed] Shulgin at best a curiosity and at worst a menace", but Bennett goes on to say that "near the end ... [Shulgin's] faith in the potential of psychedelics ha[d] at least a chance at vindication", going on to note the various clinical trials underway on compounds of interest to Shulgin. The early 2000s also was a period where Shulgin was witness to a series of incidents in which young men overdosed on a novel psychoactive agent whose preparation was disclosed by Shulgin in one of his books. Before his death (and before the onset of his late life dementia), Shulgin expressed sadness over the deaths, but argued that all drugs, including aspirin, carry risks with incorrect use. Source: Wikipedia (en)